Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study

Figures & data

Table 1. Causes of Renal Failure.

Vascular nephropathy	76
Interstitial nephropathy/pyelonephritis	34
Diabetic nephropathy	20
Glomerulonephritis	14
Others	12
Unknown	13

Table 2. Changes in Blood Pressure.

	SBP	DBP	HR
Basal	162.0 ± 16.6	93.2 ± 8.3	76.3 ± 10.3
1 month	142.8 ± 15.5a	83.1 ± 8.1a	76.2 ± 10.3
3 months	135.2 ± 12.1a	78.7 ± 6.6a	75.4 ± 10.8
6 months	131.6 ± 11.6a	78.2 ± 6.4a	74.7 ± 9.8

^aSBP and DBP are expressed as mmHg. HR is expressed as bpm. P < 0.001 versus baseline.

Figure 1. Number of controlled and responder patients at the end of follow-up, p < 0.001 versus 1.

Table 3. Biochemical Changes.

	Basal	1 month	3 months	6 months	Units
Creatinine	1.9 ± 0.5	1.9 ± 0.5	1.8 ± 0.5	1.9 ± 0.6	mg/dL
Urea	68.0 ± 31.3	69.7 ± 28.5	73.2 ± 30.3	69.2 ± 31.8	mg/dL
Urate	7.2 ± 1.8	7.0 ± 1.6	6.9 ± 1.7	6.9 ± 1.6	mg/dL
Cholesterol	221 ± 47	216 ± 41	218 ± 38	211 ± 35a	mg/dL
Triglycerides	140 ± 51	137 ± 53	139 ± 49	134 ± 45b	mg/dL
Glucose	109 ± 34	109 ± 33	103 ± 20	108 ± 34	mg/dL
Na	141 ± 2.7	141 ± 2.7	141 ± 2.6	141 ± 2.3	mmol/L
K	4.7 ± 0.5	4.7 ± 0.5	4.7 ± 0.5	4.7 ± 0.5	mmol/L
Ca	9.5 ± 0.5	9.5 ± 0.5	9.5 ± 0.6	9.4 ± 0.5	mg/dL
Creatinine clearance	41.8 ± 16.0	42.6 ± 17.7	44.6 ± 17.5	45.8 ± 18.0c	mL/min

^ap = 0.001 versus baseline.

^bp = 0.018 versus baseline.

^cp = 0.019 versus baseline.

Figure 2. Creatinine clearance steadily increases along the treatment with lercanidipine (p = 0.019).

Figure 3. Proteinuria decrease after adding lercanidipine to ACE inhibitors/ARB therapy, although this change was significant at 6 months (p = 0.015).